Table 2.
Five-year second primary malignancy rates after index oropharyngeal cancer for HPV-seronegative and HPV-seropositive patients segregated by clinical variables.
| Variable | Patients, | HPV Negative
|
HPV Positive
|
Log-rank |
|---|---|---|---|---|
| (N=102) | (N=80) | |||
| 5-yr SPM rate, % | 5-yr SPM rate, % | |||
| No. | (95% CI) | (95% CI) | p value | |
| Total | 182 | 14.6 (8.6–24.4) | 5.6 (2.1–14.3) | 0.051 |
| Subsite | ||||
| Tonsil/base of tongue | 169 | 14.1 (8.1–24.1) | 5.9 (2.2–15.1) | 0.088 |
| Other | 13 | 20.0 (3.1–79.6) | 0.0 | 0.246 |
| Histologic grade* | ||||
| Well | 8 | 0.0 | 0.0 | -- |
| Moderate – Poor | 147 | 15.1 (8.4–26.3) | 4.8 (1.6–14.2) | 0.029 |
| Not recorded | 27 | 16.1 (4.3–50.6) | 11.1 (1.6–56.7) | 0.990 |
| T classification | ||||
| 1 or 2 | 103 | 11.4 (5.3–23.6) | 2.5 (0.4–16.5) | 0.107 |
| 3 or 4 | 79 | 20.3 (9.5–40.4) | 10.2 (3.4–28.8) | 0.264 |
| N classification | ||||
| 0 | 27 | 13.5 (3.5–44.2) | 0.0 | 0.331 |
| 1–3 | 155 | 14.9 (8.3–26.0) | 6.2 (2.4–15.7) | 0.084 |
| TNM stage | ||||
| I or II | 12 | 16.7 (2.5–72.7) | 0.0 | 0.607 |
| III or IV | 170 | 14.5 (8.3–24.7) | 5.9 (2.2–14.9) | 0.075 |
| Treatment | ||||
| Radiation | 79 | 21.1 (10.6–39.3) | 2.0 (0.3–13.4) | 0.005 |
| Chemoradiation | 84 | 12.2 (5.3–27.0) | 13.7 (4.5–37.6) | 0.606 |
| Other | 19 | 0.0 | 0.0 | 0.183 |
Abbreviations: CI, confidence interval; HPV, human papillomavirus; SPM, second primary malignancy.
*
Well category includes grades of well differentiated and moderately well differentiated tumors. Moderate – Poor category includes grades of moderately, moderately poorly, and poorly differentiated tumors.